176 related articles for article (PubMed ID: 37568755)
1. Therapeutic Potential of Targeting the Cytochrome P450 Enzymes Using Lopinavir/Ritonavir in Colorectal Cancer: A Study in Monolayers, Spheroids and In Vivo Models.
Alaei M; Nazari SE; Pourali G; Asadnia A; Moetamani-Ahmadi M; Fiuji H; Tanzadehpanah H; Asgharzadeh F; Babaei F; Khojasteh-Leylakoohi F; Saeed Gataa I; Ali Kiani M; Ferns GA; Lam AK; Hassanian SM; Khazaei M; Giovannetti E; Avan A
Cancers (Basel); 2023 Aug; 15(15):. PubMed ID: 37568755
[TBL] [Abstract][Full Text] [Related]
2. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS; Goa KL
Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the Wnt/b-catenin pathway using PNU-74654 reduces tumor growth in in vitro and in vivo models of colorectal cancer.
Amerizadeh F; Rahmani F; Maftooh M; Nasiri SN; Hassanian SM; Giovannetti E; Moradi-Marjaneh R; Sabbaghzadeh R; Shahidsales S; Joudi-Mashhad M; Ghayour-Mobarhan M; Ferns GA; Khazaei M; Avan A
Tissue Cell; 2022 Aug; 77():101853. PubMed ID: 35803035
[TBL] [Abstract][Full Text] [Related]
4. Darunavir: a review of its use in the management of HIV infection in adults.
McKeage K; Perry CM; Keam SJ
Drugs; 2009; 69(4):477-503. PubMed ID: 19323590
[TBL] [Abstract][Full Text] [Related]
5. Crocin synergistically enhances the antiproliferative activity of 5-flurouracil through Wnt/PI3K pathway in a mouse model of colitis-associated colorectal cancer.
Amerizadeh F; Rezaei N; Rahmani F; Hassanian SM; Moradi-Marjaneh R; Fiuji H; Boroumand N; Nosrati-Tirkani A; Ghayour-Mobarhan M; Ferns GA; Khazaei M; Avan A
J Cell Biochem; 2018 Dec; 119(12):10250-10261. PubMed ID: 30129057
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of angiotensin II type 1 receptor by candesartan reduces tumor growth and ameliorates fibrosis in colorectal cancer.
Tabatabai E; Khazaei M; Asgharzadeh F; Nazari SE; Shakour N; Fiuji H; Ziaeemehr A; Mostafapour A; Parizadeh MR; Nouri M; Hassanian SM; Hadizadeh F; Ferns GA; Rahmati M; Rahmani F; Avan A
EXCLI J; 2021; 20():863-878. PubMed ID: 34121975
[TBL] [Abstract][Full Text] [Related]
7. Echinacea purpurea significantly induces cytochrome P450 3A activity but does not alter lopinavir-ritonavir exposure in healthy subjects.
Penzak SR; Robertson SM; Hunt JD; Chairez C; Malati CY; Alfaro RM; Stevenson JM; Kovacs JA
Pharmacotherapy; 2010 Aug; 30(8):797-805. PubMed ID: 20653355
[TBL] [Abstract][Full Text] [Related]
8. Phytosomal curcumin inhibits tumor growth in colitis-associated colorectal cancer.
Marjaneh RM; Rahmani F; Hassanian SM; Rezaei N; Hashemzehi M; Bahrami A; Ariakia F; Fiuji H; Sahebkar A; Avan A; Khazaei M
J Cell Physiol; 2018 Oct; 233(10):6785-6798. PubMed ID: 29737515
[TBL] [Abstract][Full Text] [Related]
9. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers.
Yeh RF; Gaver VE; Patterson KB; Rezk NL; Baxter-Meheux F; Blake MJ; Eron JJ; Klein CE; Rublein JC; Kashuba AD
J Acquir Immune Defic Syndr; 2006 May; 42(1):52-60. PubMed ID: 16639344
[TBL] [Abstract][Full Text] [Related]
10. CYP3A4-mediated lopinavir bioactivation and its inhibition by ritonavir.
Li F; Lu J; Ma X
Drug Metab Dispos; 2012 Jan; 40(1):18-24. PubMed ID: 21953914
[TBL] [Abstract][Full Text] [Related]
11. Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir.
van Waterschoot RA; ter Heine R; Wagenaar E; van der Kruijssen CM; Rooswinkel RW; Huitema AD; Beijnen JH; Schinkel AH
Br J Pharmacol; 2010 Jul; 160(5):1224-33. PubMed ID: 20590614
[TBL] [Abstract][Full Text] [Related]
12. AMP-kinase inhibitor dorsomorphin reduces the proliferation and migration behavior of colorectal cancer cells by targeting the AKT/mTOR pathway.
Ghanaatgar-Kasbi S; Amerizadeh F; Rahmani F; Hassanian SM; Khazaei M; Ferns GA; Avan A
IUBMB Life; 2019 Dec; 71(12):1929-1936. PubMed ID: 31359579
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
[TBL] [Abstract][Full Text] [Related]
14. Influence of Panax ginseng on the steady state pharmacokinetic profile of lopinavir-ritonavir in healthy volunteers.
Calderón MM; Chairez CL; Gordon LA; Alfaro RM; Kovacs JA; Penzak SR
Pharmacotherapy; 2014 Nov; 34(11):1151-8. PubMed ID: 25142999
[TBL] [Abstract][Full Text] [Related]
15. The dual protease inhibitor lopinavir/ritonavir (LPV/r) exerts genotoxic stress on lung cells.
Marima R; Hull R; Dlamini Z; Penny C
Biomed Pharmacother; 2020 Dec; 132():110829. PubMed ID: 33059259
[TBL] [Abstract][Full Text] [Related]
16. Assessing the impact of hepatitis C virus coinfection on lopinavir/ritonavir trough concentrations in HIV-infected patients.
Calza L; Mosca L; Pocaterra D; Piergentili B; Colangeli V; Manfredi R; Erario A; Grossi G; Verucchi G; Viale P
Eur J Clin Pharmacol; 2011 Feb; 67(2):143-9. PubMed ID: 20878151
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of CYP3A7 DHEA-S Oxidation by Lopinavir and Ritonavir: An Alternative Mechanism for Adrenal Impairment in HIV Antiretroviral-Treated Neonates.
Kandel SE; Lampe JN
Chem Res Toxicol; 2021 Apr; 34(4):1150-1160. PubMed ID: 33821626
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers.
la Porte CJ; Colbers EP; Bertz R; Voncken DS; Wikstrom K; Boeree MJ; Koopmans PP; Hekster YA; Burger DM
Antimicrob Agents Chemother; 2004 May; 48(5):1553-60. PubMed ID: 15105105
[TBL] [Abstract][Full Text] [Related]
19. An integrated pharmacokinetic model for the influence of CYP3A4 expression on the in vivo disposition of lopinavir and its modulation by ritonavir.
ter Heine R; Van Waterschoot RA; Keizer RJ; Beijnen JH; Schinkel AH; Huitema AD
J Pharm Sci; 2011 Jun; 100(6):2508-15. PubMed ID: 21491455
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of angiotensin pathway via valsartan reduces tumor growth in models of colorectal cancer.
Asgharzadeh F; Mostafapour A; Ebrahimi S; Amerizadeh F; Sabbaghzadeh R; Hassanian SM; Fakhraei M; Farshbaf A; Ferns GA; Giovannetti E; Avan A; Khazaei M
Toxicol Appl Pharmacol; 2022 Apr; 440():115951. PubMed ID: 35235860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
